Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors

被引：0
|
作者：
Chenard-Poirier, Maxime
Almhanna, Khaldoun
Lim, Darren Wan-Teck
El-Khoueiry, Anthony B.
Samol, Jens
Ryoo, Baek-Yeol
Hong, Jung Yong
Meng, Robin
Abbadessa, Giovanni
Masciari, Serena
Kefsi, Asma
Zhang, Yiding
Guillemin-Paveau, Helene
Pasquier, Benoit
Lepine, Lucie
Dumbrava, Ecaterina Elena
机构：
[1] CHU Quebec Univ Laval, Quebec City, PQ, Canada
[2] Brown Univ, Lifespan Canc Inst, Warren Alpert Med Sch, Providence, RI USA
[3] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[4] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Tan Tock Seng Hosp, Singapore, Singapore
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Lee Kong Chian NTU, Singapore, Singapore
[8] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[10] Sanofi, Cambridge, MA USA
[11] Sanofi, Vitry Sur Seine, France
[12] Sanofi, Chilly Mazarin, France
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2579
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
    Hong, J. Yong
    Ryoo, B-Y.
    Chenard-Poirier, M.
    Almhanna, K.
    Lim, D. W. T.
    Samol, J.
    Abbadessa, G.
    Meng, R.
    Masciari, S.
    Kefsi, A.
    Zhang, Y.
    Guillemin-Paveau, H.
    Pasquier, B.
    Lepine, L.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S634 - S634
  • [2] Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
    Moreno Garcia, V.
    Oh, D-Y.
    Ryu, M. H.
    Calvo, E.
    Garralda, E.
    Chung, W-P.
    Bai, L-Y.
    Rojas Laimito, K. I.
    Yildirim, O.
    Masciari, S.
    Mi, G.
    Wang, L.
    Kanlikilicer, P.
    Buday, B.
    Rharbaoui, F.
    Abbadessa, G.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S518 - S518
  • [3] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [4] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [5] An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
    Shumaker, Robert
    Ren, Min
    Aluri, Jagadeesh
    Dutcus, Corina E.
    Rance, Christian
    He, Cixin
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (03) : 373 - 383
  • [6] An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
    Robert Shumaker
    Min Ren
    Jagadeesh Aluri
    Corina E. Dutcus
    Christian Rance
    Cixin He
    European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 373 - 383
  • [7] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael S.
    Wolf, Ido
    Fakih, Marwan
    de Vos-Geelen, Judith
    Lee, Valerie
    Vogel, Arndt
    Wu, Xi Lawrence
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [10] Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
    Shen, Lin
    Guo, Jun
    Zhang, Qingyuan
    Pan, Hongming
    Yuan, Ying
    Bai, Yuxian
    Liu, Tianshu
    Zhou, Qing
    Zhao, Jun
    Shu, Yongqian
    Huang, Xiaoming
    Wang, Siyang
    Wang, Jie
    Zhou, Aiping
    Ye, Dingwei
    Sun, Ting
    Gao, Yujuan
    Yang, Silu
    Wang, Zoubai
    Li, Jian
    Wu, Yi-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345